OSX secures distribution for autologous dentin bone graft
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Osteopore Ltd. has secured distribution rights for a new autologous dentin graft technology process, enhancing its regenerative dental portfolio in Singapore and potentially expanding into the ASEAN/APAC markets. This innovative process allows for the rapid conversion of extracted teeth into graft material, which retains natural properties beneficial for bone regeneration. The CEO emphasized that this addition strengthens their product offerings in dentistry and aligns with their mission to improve patient outcomes through regenerative medicine.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Osteopore
- Appendix 4E Preliminary Final Report
- Drawdown of Tranche 2 of the Redeemable Convertible Notes
- OSX secures Latin America deal for craniofacial distribution
- Osteopore Secures Latin America Deal For Craniofacial Distribution
- Further Drawdown of T1 of the Redeemable Convertible Notes
Later from Osteopore
- OSX signs agreement for injectable regenerative bone filler
- Clarification - agreement for injectable regen bone filler
- Further Drawdown of T2 of the Redeemable Convertible Notes
- Activities Report March 2026 and Appendix 4C
- OSX secures Hainan FDA approval for orthopaedic devices
Follow Osteopore into a list and get an email when it puts out news.
Follow Osteopore